Allogenic Advance
A step closer to an off-the-shelf CAR T cell therapy
James Strachan | | Quick Read
Two-out-of-four patients in a 300 million-cell cohort, and one-out-of-three in a 100-cell cohort, achieved a complete response following treatment with CRISPR Therapeutics’ allogeneic CAR T cell therapy CTX110 (1).
The B-cell malignancy treatment was safe at the 300-million dose level and below. The only patient who received a 600 million-cell dose, after initially achieving a complete response, was hospitalized with febrile neutropenia and later died after reactivation of HHV-6 and HHV-6 encephalitis.
CTX110 is derived from healthy donor T cells, which are modified using CRISPR/Cas 9 to i) insert a CAR construct, which binds to cancer cells and activates T cells and ii) knock out the T cell receptor and MHC1, which reduces the risk of graft versus host disease and rejection.
Enjoy our FREE content!
Log in or register to gain full unlimited access to all content on the The Medicine Maker site. It’s FREE!
Login
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
- CRISPR Therapeutics (2020). Available at: bit.ly/2TxT5Ag
About the Author
